The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis
Abstract
BACKGROUND: The utility of antineutrophil cytoplasmic antibody (ANCA) levels to guide the management of patients with Wegener granulomatosis remains controversial. OBJECTIVE: To determine whether pro-proteinase 3 (PR3)-ANCA levels are a better measure of disease activity than mature-PR3-ANCA levels, whether decreases in either level are associated with shorter time to remission, and whether increases are followed by relapse. DESIGN: Prospective, observational cohort study. SETTING: 8 United States medical centers that participated in a treatment trial for Wegener granulomatosis. PATIENTS: 156 patients with Wegener granulomatosis enrolled during periods of active disease. MEASUREMENTS: PR3-ANCA levels (by capture enzyme-linked immunosorbent assay) and disease activity (by the Birmingham Vasculitis Activity Score for Wegener granulomatosis). RESULTS: The ANCA levels were only weakly associated with disease activity across patients. The longitudinal association within patients was stronger, but changes in ANCA levels explained less than 10% of the variation in disease activity. Decreases in mature- and pro-PR3-ANCA levels were not statistically significantly associated with shorter time to remission, and increases in mature-PR3-ANCA levels (adjusted hazard ratio, 0.8 [95% CI, 0.4 to 1.9]; P = 0.67) and pro-PR3-ANCA levels (adjusted hazard ratio, 1.0 [CI, 0.5 to 2.1]; P = 0.99) were not associated with relapse. The proportion of patients who had relapse within 1 year of an increase in PR3-ANCA levels was 40% for mature-PR3 (CI, 18% to 56%) and 43% for pro-PR3 (CI, 22% to 58%). LIMITATIONS: Samples were collected approximately every 3 months. Sensitivity and specificity of ANCA levels for detecting remission and relapse could not be calculated because each patient had different follow-up times. CONCLUSION: Pro-PR3-ANCA is no better than mature-PR3-ANCA as a measure of Wegener granulomatosis activity. Decreases in PR3-ANCA levels are not associated with shorter time to remission, and increases are not associated with relapse. These findings suggest that ANCA levels cannot be used to guide immunosuppressive therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
Self-citationVan Der Woude, F. J., Lobatto, S., Permin, H., Van Der Giessen, M., Rasmussen, N., Wiik, A., Van Es, L. A., Van Der Hem, G. K., & The, T. H. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91147-x · Cited by 1,885
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348
Etanercept plus Standard Therapy for Wegener's Granulomatosis
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa041884 · Cited by 834
De Groot, K., Rasmussen, N., Bacon, P. A., Tervaert, J. W. C., Feighery, C., Gregorini, G., Gross, W. L., Luqmani, R., & Jayne, D. R. W. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21142 · Cited by 801
Reinhold-Keller, E., Beuge, N., Latza, U., De Groot, K., Rudert, H., Nölle, B., Heller, M., & Gross, W. L. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200005)43:5<1021::aid-anr10>3.0.co;2-j · Cited by 696
Association Between Active Wegener's Granulomatosis and Anticytoplasmic Antibodies
Tervaert, J. W. C. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.11.2461 · Cited by 517
Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study
Booth, A. D., Almond, M. K., Burns, A., Ellis, P., Gaskin, G., Neild, G. H., Plaisance, M., Pusey, C. D., & Jayne, D. R. W. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00025-8 · Cited by 504
Antineutrophil cytoplasmic antibodies
Hoffman, G. S., & Specks, U. (1998) · Arthritis & Rheumatism · Cited by 472
Self-citationBoomsma, M. M., Stegeman, C. A., Van Der Leij, M. J., Oost, W., Hermans, J., Kallenberg, C. G. M., Limburg, P. C., & Tervaert, J. W. C. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200009)43:9<2025::aid-anr13>3.0.co;2-o · Cited by 434
Cited by
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Yates, M., Watts, R. A., Bajema, I. M., Cid, M. C., Crestani, B., Hauser, T., Hellmich, B., Holle, J. U., Laudien, M., Little, M. A., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209133 · Cited by 1,194
Self-citationGenetically Distinct Subsets within ANCA-Associated Vasculitis
Lyons, P. A., Rayner, T. F., Trivedi, S., Holle, J. U., Watts, R. A., Jayne, D. R. W., Baslund, B., Brenchley, P., Bruchfeld, A., Chaudhry, A. N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108735 · Cited by 1,010
EULAR recommendations for the management of primary small and medium vessel vasculitis
Mukhtyar, C., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W., Hauser, T., Hellmich, B., Jayne, D., Kallenberg, C. G. M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088096 · Cited by 990
Self-citationKitching, A. R., Anders, H.-J., Basu, N., Brouwer, E., Gordon, J., Jayne, D. R., Kullman, J., Lyons, P. A., Merkel, P. A., Savage, C. O. S., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0204-y · Cited by 928
Self-citationAzathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis
Dhawan, R. (2009) · Yearbook of Medicine · doi:10.1016/s0084-3873(09)79350-2 · Cited by 674
Metadata
- Authors
- Finkielman, J. D., Merkel, P. A., Schroeder, D., Hoffman, G. S., Spiera, R., St. Clair, E. W., Davis, J. C., McCune, W. J., Lears, A. K., Ytterberg, S. R., Hummel, A. M., Viss, M. A., Peikert, T., Stone, J. H., Specks, U., & for the WGET Research Group
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2007-11-06
- Volume
- 147
- Issue
- 9
- Pages
- 611-619
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2098084886
- Cited by
- 265
- References
- 23
- FWCI
- 19.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis. https://app.cochat.ai/papers/10.7326/0003-4819-147-9-200711060-00005
- The paper
- Finkielman, J. D., Merkel, P. A., Schroeder, D., Hoffman, G. S., Spiera, R., St. Clair, E. W., Davis, J. C., McCune, W. J., Lears, A. K., Ytterberg, S. R., Hummel, A. M., Viss, M. A., Peikert, T., Stone, J. H., Specks, U., & for the WGET Research Group. (2007). Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-147-9-200711060-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.